Physician profile
Max C Kim
NPI 1851300461
$10,315.72
in general payments reported to CMS, 2019-2025
26 companies · $1,612 in 2025
The $1,612 reported for 2025 was more than what 75% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,699 · 2020: $1,137 · 2021: $1,029 · 2022: $1,044 · 2023: $621 · 2024: $1,173 · 2025: $1,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,406.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,703.40 | 2019 | |
| Aerie Pharmaceuticals, INC. | $1,220.77 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $1,192.13 | 2019-2025 | Xelpros, Cequa, Bromsite |
| Alcon Vision LLC | $1,153.71 | 2021-2025 | Rocklatan, Hydrus Microstent, Acrysof Iq Panoptix Uv Iol |
| Glaukos Corporation | $801.25 | 2023-2025 | Idosetr, Idose |
| Abbvie INC. | $668.70 | 2023-2025 | |
| Allergan, INC. | $657.45 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $441.29 | 2019-2021 | |
| Rxsight INC | $368.46 | 2022-2024 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb Americas INC. | $292.15 | 2022-2025 | Vyzulta, Miebo |
| Dompe US, INC. | $286.83 | 2019-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $238.71 | 2019-2021 | |
| Ivantis, INC | $224.72 | 2019-2020 | |
| Thea Pharma INC. | $175.84 | 2022-2025 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $168.48 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $136.59 | 2019 | |
| Sight Sciences, INC. | $136.44 | 2020-2024 | Omni Surgical System |
| Apellis Pharmaceuticals, INC. | $106.63 | 2025 | Syfovre |
| Genentech USA, INC. | $81.04 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $73.65 | 2023 | Clarus |
| Heidelberg Engineering, INC. | $67.73 | 2023 | Spectralis |
| New World Medical,INC. | $34.54 | 2023-2025 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Ocular Therapeutix, INC. | $26.07 | 2025 | Dextenza |
| Akorn Operating Company LLC | $23.54 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Rayner Intraocular Lenses Limited | $16.20 | 2023 | Rayone Aspheric, Rayone Emv, Omidria |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.